ImpediMed Raises A$15.2 Million to Fuel Growth and Cut Costs

Capital Raise Strengthens Balance Sheet Amid US Market Expansion

ImpediMed Limited (ASX:IPD) has successfully raised A$15.2 million through a two-tranche institutional placement and a share purchase plan (SPP), priced at A$0.010 per share, representing a near 29% discount to recent trading prices. The raise attracted strong support from both new and existing institutional investors, including A$0.6 million committed by company directors. Participants will receive attaching options exercisable in 2027, subject to shareholder approval at a June extraordinary general meeting (EGM).

The proceeds will be split between partially prepaying the company’s SWK Growth Capital Facility, reducing annual interest costs by approximately A$0.7 million, and funding growth initiatives, particularly commercial expansion of its SOZO® platform in the US. This capital injection follows a recent operational update highlighting a steady increase in annual recurring revenue (ARR) to A$14.1 million and expanded payer coverage for its breast cancer-related lymphoedema (BCRL) technology, now covering 93% of the US insured population. The company is also actively commercialising SOZO® Pro in Heart Health and Weight Management markets, two segments with combined total addressable markets exceeding US$1 billion. This equity raise builds on momentum from the company’s recent growth in US Heart Health push and the appointment of Erik Anderson as CEO to accelerate US commercial growth.

Operational Cost Reductions and Debt Prepayment to Reset Financial Trajectory

Alongside the capital raise, ImpediMed is implementing operational initiatives expected to deliver A$5 million in annualised cost savings commencing July 2026. These include headcount reductions, consolidation of finance and administrative roles, relocation of non-revenue functions, and a reduction in hardware engineering costs following the SOZO® Pro launch. The combined effect of cost-cutting and partial debt repayment is projected to improve profit before tax by around 25% on a pro forma basis, setting the stage for operating cashflow breakeven in the second half of FY28, assuming full exercise of the attaching options.

The company’s pro forma net cash position post-raise and debt prepayment stands at approximately A$5.9 million. This deleveraging is critical given covenant tests on the SWK facility were deferred conditional on the capital raise and cost reductions. Failure to meet these conditions would have risked default and accelerated debt repayment. The company’s management is confident that the combined capital and cost initiatives will satisfy lender conditions and provide a more sustainable financial footing.

SOZO® Platform Positioned for Multi-Segment Growth with Strong Clinical and Reimbursement Backing

ImpediMed’s SOZO® Digital Health Platform, which uses bioimpedance spectroscopy (BIS) technology, remains the only FDA-cleared device for objective detection and surveillance of fluid status across multiple indications including BCRL, heart failure, and weight management. The platform boasts a solid installed base with over 600 devices in leading US cancer centres and a pipeline exceeding 700 devices, representing nearly A$35 million in total contract value.

SOZO® benefits from strong clinical evidence, national US reimbursement coverage exceeding 93% for BCRL, and endorsements in multiple medical guidelines such as NCCN and NAPBC. The launch of SOZO® Pro in FY26 targets adjacent high-growth markets in Heart Health (~US$600 million TAM) and Weight Management (~US$425 million TAM), leveraging existing relationships with 17 of the top 20 integrated delivery networks (IDNs) by patient revenue. Early sales have been recorded in Heart Health, driven by the urgent clinical need for objective fluid status assessment to prevent heart failure readmissions, a costly and prevalent US healthcare challenge.

These market expansions are underpinned by rising demand for objective monitoring tools, including the growing use of GLP-1 therapies for weight management, with new guidelines recommending personalized body composition assessments. SOZO® Pro’s non-invasive 30-second test offers clinicians actionable data on fluid overload and body composition, positioning it as a valuable adjunct to traditional monitoring methods.

Shareholder Approval and Dilution Risks Ahead

The completion of the capital raise is contingent on shareholder approval of the tranche 2 placement and the issuing of attaching options at the upcoming EGM scheduled for 11 June 2026. If approval is not granted, the company risks not raising the full intended amount, which could jeopardize the planned debt prepayment and cost reduction initiatives, potentially triggering covenant breaches under the SWK facility.

The raise will increase the total shares on issue from approximately 2.04 billion to 3.54 billion, diluting existing shareholders by about 42%, assuming no prior option exercises. While the attaching options offer potential upside, their exercise is uncertain and subject to market conditions and shareholder approval. Investors should weigh the dilution impact against the company’s strengthened balance sheet and growth prospects.